{"id":"821","post_author":null,"post_date":null,"post_date_gmt":null,"post_content":null,"post_title":"InVivoSIM anti-human sclerostin (SOST) (Romosozumab Biosimilar)","post_excerpt":"This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Romosozumab, making it ideal for research use. Romosozumab is a humanized IgG2\u03ba monoclonal antibody that targets sclerostin (SOST), a secreted glycoprotein produced by osteocytes. Sclerostin negatively regulates bone formation by binding LRP4\/5\/6 and inhibiting Wnt\/\u03b2\u2011catenin signaling\u2014a key pathway for osteoblast activity. By neutralizing sclerostin, Romosozumab promotes bone formation while simultaneously suppressing bone resorption. This Romosozumab biosimilar is intended for non-therapeutic research use and can support studies on osteoanabolic mechanisms, Wnt signaling, and sclerostin function in bone biology.","post_status":"publish","comment_status":null,"ping_status":null,"post_password":null,"post_name":"invivosim-anti-human-sclerostin-sost-romosozumab-biosimilar-sim0068","to_ping":null,"pinged":null,"post_modified":null,"post_modified_gmt":null,"post_content_filtered":null,"post_parent":null,"guid":null,"menu_order":null,"post_type":null,"post_mime_type":null,"comment_count":null,"filter":null,"sku":"SIM0068","path":"\/product\/invivosim-anti-human-sclerostin-sost-romosozumab-biosimilar-sim0068\/","image":"https:\/\/pneuma.bioxcell.com\/Media\/Products\/bioxcell-sim0068-invivosim-anti-human-sclerostin-sost-romosozumab-biosimilar.png","brand_id":null,"brand_name":null,"brand_slug":null,"brand_description":null,"isotype":"Human IgG2, \u03ba","immunogen":"Human SOST","reported_applications":"In vitro and ex vivo assays of sclerostin neutralization\nELISA\nWestern blot\nFlow cytometry","aggregation":"<5%\nDetermined by SEC","formulation":"PBS, pH 7.0\nContains no stabilizers or preservatives","murine_pathogen_tests":"Mouse Norovirus: Negative\nMouse Parvovirus: Negative\nMouse Minute Virus: Negative\nMouse Hepatitis Virus: Negative\nReovirus Screen: Negative\nLymphocytic Choriomeningitis virus: Negative\nLactate Dehydrogenase-Elevating Virus: Negative\nMouse Rotavirus: Negative\nTheiler's Murine Encephalomyelitis: Negative\nEctromelia\/Mousepox Virus: Negative\nHantavirus: Negative\nPolyoma Virus: Negative\nMouse Adenovirus: Negative\nSendai Virus: Negative\nMycoplasma Pulmonis: Negative\nPneumonia Virus of Mice: Negative\nMouse Cytomegalovirus: Negative\nK Virus: Negative","human_pathogen_tests":"","toxicity_test_results":null,"endotoxin":"<ul><li>\u22640.5EU\/mg (\u22640.0005EU\/\u03bcg)<\/li><li>Determined by LAL gel clotting assay<\/li><\/ul>","purity":"<ul><li>\u226595%<\/li><li>Determined by SDS-PAGE<\/li><\/ul>","sterility":"0.2 \u03bcm filtration","production":"Purified from cell culture supernatant in an animal-free facility","purification":"Protein A","composition":null,"volume":null,"concentration":null,"molecular_weight":"150 kDa","storage":"The antibody solution should be stored at the stock concentration at 4\u00b0C. Do not freeze.","rrid":"","recommended_isotype_control":"<a href=\"\/product\/\">RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme<\/a>","recommended_dilution_buffer":"<a href=\"\/product\/\">InVivoPure pH 6.0T Dilution Buffer<\/a>","clone":"Romosozumab","technical_data_sheet":"https:\/\/pneuma.bioxcell.com\/api\/v1\/products\/certificate-of-analysis\/SIM0068\/0\/0\/0?apikey=23D50188E6F74755AFFBF95BD41B140B","western_blot_image":null,"new_product_image":null,"product_references":null,"display_pubmed_logo":null,"modified":"2026-03-18 02:10:05","active":"Y"}

InVivoSIM anti-human sclerostin (SOST) (Romosozumab Biosimilar)

Clone	Catalog #	Category
Romosozumab	SIM0068

USD 235 - USD 8140

Technical Data Sheet

SDS Sheet

About InVivoSIM anti-human sclerostin (SOST) (Romosozumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Romosozumab, making it ideal for research use. Romosozumab is a humanized IgG2κ monoclonal antibody that targets sclerostin (SOST), a secreted glycoprotein produced by osteocytes. Sclerostin negatively regulates bone formation by binding LRP4/5/6 and inhibiting Wnt/β‑catenin signaling—a key pathway for osteoblast activity. By neutralizing sclerostin, Romosozumab promotes bone formation while simultaneously suppressing bone resorption. This Romosozumab biosimilar is intended for non-therapeutic research use and can support studies on osteoanabolic mechanisms, Wnt signaling, and sclerostin function in bone biology.

InVivoSIM anti-human sclerostin (SOST) (Romosozumab Biosimilar) Specifications

Isotype	Human IgG2, κ
Recommended Isotype Control(s)	RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer	InVivoPure pH 6.0T Dilution Buffer
Immunogen	Human SOST
Reported Applications	In vitro and ex vivo assays of sclerostin neutralization ELISA Western blot Flow cytometry
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay
Aggregation	<5% Determined by SEC
Purity	≥95% Determined by SDS-PAGE
Sterility	0.2 μm filtration
Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A
Molecular Weight	150 kDa
Storage	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.